To The Editor:We read with interest the recent paper "The Cost-Effectiveness of
Extended-Duration Antithrombotic Prophylaxis After Total Hip
Arthroplasty" (2007;89:819-28), by Skedgel et al., regarding economic
decision-making, with reference to extended thromboprophylaxis after total hip
arthroplasty. The authors refer to a study by Lapidus et al.1, who
stated that 38.4% of patients receiving low-molecular-weight heparin required
a community nurse for administration. For cost-effectiveness, the number
requiring a community nurse must be <10%.